drugset / Trial / NCT06524583
Interest of Post-operative Chemotherapy in Patients With Localised Uterine Leiomyosarcoma Suspected of Having a High Risk of Recurrence Based on a Biological Test Performed on the Tumour
Phase 2
Recruiting
198 enrolled
UNICANCER
Institut Bergonié · collabInstitut Claudius Regaud · collabLigue contre le cancer, France · collabNational Research Agency, France · collabOncopole · collabPharmaMar · collabUniversity Hospital, Marseille · collab
RandomizedParallel-groupOpen-labelPrevention
Summary
Addition of postoperative chemotherapy to prevent or delay recurrence in patients newly diagnosed with localized uterine leiomyosarcoma and who have undergone complete tumor surgery.
Timeline
- Start
- 2025-01-27
- Primary completion
- 2029-12
- Completion
- 2030-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Doxorubicin | Other / unclassified | 60 mg/m2 | Intravenous |
| Subject | Trabectedin | Small molecule | 1.1 mg/m2 | Intravenous |